Monopar Therapeutics MNPR Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's payments to acquire short-term investments?
- Monopar Therapeutics (MNPR) reported payments to acquire short-term investments of $40.84M in Q1 2026.
- How has Monopar Therapeutics's payments to acquire short-term investments changed year-over-year?
- Monopar Therapeutics's payments to acquire short-term investments increased by 2020.5% year-over-year, from $1.93M to $40.84M.
- What is the long-term trend for Monopar Therapeutics's payments to acquire short-term investments?
- Over 2 years (2023 to 2025), Monopar Therapeutics's payments to acquire short-term investments has grown at a 232.3% compound annual growth rate (CAGR), from $7.89M to $87.15M.